JP2018507245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507245A5 JP2018507245A5 JP2017546767A JP2017546767A JP2018507245A5 JP 2018507245 A5 JP2018507245 A5 JP 2018507245A5 JP 2017546767 A JP2017546767 A JP 2017546767A JP 2017546767 A JP2017546767 A JP 2017546767A JP 2018507245 A5 JP2018507245 A5 JP 2018507245A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor
- brain tumor
- brain
- purinaburin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003174 Brain Neoplasms Diseases 0.000 claims 12
- 206010003571 Astrocytoma Diseases 0.000 claims 5
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 claims 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 claims 1
- 208000037156 Choroid plexus tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008846 Neurocytoma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000015632 childhood ependymoma Diseases 0.000 claims 1
- 201000007369 choroid plexus cancer Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 201000011610 giant cell glioblastoma Diseases 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000000389 pediatric ependymoma Diseases 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129623P | 2015-03-06 | 2015-03-06 | |
| US62/129,623 | 2015-03-06 | ||
| US201562249807P | 2015-11-02 | 2015-11-02 | |
| US62/249,807 | 2015-11-02 | ||
| PCT/US2016/020396 WO2016144636A1 (en) | 2015-03-06 | 2016-03-02 | Method of treating a brain tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021026411A Division JP7264331B2 (ja) | 2015-03-06 | 2021-02-22 | 脳腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507245A JP2018507245A (ja) | 2018-03-15 |
| JP2018507245A5 true JP2018507245A5 (https=) | 2019-04-11 |
| JP6904570B2 JP6904570B2 (ja) | 2021-07-21 |
Family
ID=56880412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546767A Active JP6904570B2 (ja) | 2015-03-06 | 2016-03-02 | 脳腫瘍の治療方法 |
| JP2021026411A Active JP7264331B2 (ja) | 2015-03-06 | 2021-02-22 | 脳腫瘍の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021026411A Active JP7264331B2 (ja) | 2015-03-06 | 2021-02-22 | 脳腫瘍の治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10076518B2 (https=) |
| EP (1) | EP3265091A4 (https=) |
| JP (2) | JP6904570B2 (https=) |
| KR (1) | KR102623404B1 (https=) |
| CN (1) | CN107530340B (https=) |
| AU (2) | AU2016229295B2 (https=) |
| BR (1) | BR112017018964A2 (https=) |
| CL (1) | CL2017002242A1 (https=) |
| HK (1) | HK1249051A1 (https=) |
| IL (1) | IL254262A0 (https=) |
| MX (1) | MX385914B (https=) |
| MY (1) | MY194341A (https=) |
| RU (1) | RU2728796C2 (https=) |
| SG (1) | SG11201707128TA (https=) |
| WO (1) | WO2016144636A1 (https=) |
| ZA (1) | ZA201706035B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| MX383691B (es) * | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| EP4093398B1 (en) * | 2020-01-22 | 2025-03-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Abt-751 and ionizing radiation for use in treating a brain tumor |
| US20230181499A1 (en) * | 2020-04-10 | 2023-06-15 | Lantern Pharma Inc. | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer |
| KR20230130044A (ko) * | 2021-01-08 | 2023-09-11 | 랜턴 파마 인코포레이티드 | 일루딘 또는 하이드록시우레아메틸 아실풀벤을 사용한뇌 전이 및 cns 전이의 치료 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509164A (https=) | 1973-05-11 | 1975-01-30 | ||
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPS6411523A (en) | 1987-07-06 | 1989-01-17 | Kawashima Tekko Kk | Dish feeder in tableware washing machine |
| JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| ES2224200T3 (es) | 1992-11-27 | 2005-03-01 | Mayne Pharma (Usa) Inc. | Composicion inyectable estable de paclitaxel. |
| JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| EP2201945B1 (en) | 1997-11-21 | 2013-03-06 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety |
| PL342254A1 (en) | 1998-01-29 | 2001-06-04 | Aventis Pharm Prod Inc | Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| PL343249A1 (en) | 1998-03-26 | 2001-07-30 | Shionogi & Co | Indole derivatives with antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| BRPI0017067B8 (pt) | 2000-01-18 | 2021-05-25 | Beyondspring Pharmaceuticals Inc | inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto |
| ATE417614T1 (de) | 2000-05-09 | 2009-01-15 | Angiorx Corp | Piperazindion-verbindungen |
| WO2002064592A1 (en) | 2000-12-28 | 2002-08-22 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| BR0313363A (pt) | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1711487A1 (en) * | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| DE202004018940U1 (de) | 2004-12-07 | 2006-04-13 | Asf Verwaltungs Gmbh | Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| AU2007207465B2 (en) * | 2006-01-18 | 2012-12-06 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| EP2571577A1 (en) | 2010-05-17 | 2013-03-27 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| US20130131018A1 (en) * | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
| WO2012035436A1 (en) | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
| JP6411523B2 (ja) | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| AU2016219204B2 (en) | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| AU2018236168B2 (en) | 2017-03-13 | 2024-02-29 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
-
2016
- 2016-03-02 HK HK18108933.3A patent/HK1249051A1/zh unknown
- 2016-03-02 SG SG11201707128TA patent/SG11201707128TA/en unknown
- 2016-03-02 MX MX2017011375A patent/MX385914B/es unknown
- 2016-03-02 KR KR1020177026283A patent/KR102623404B1/ko active Active
- 2016-03-02 CN CN201680020652.9A patent/CN107530340B/zh active Active
- 2016-03-02 RU RU2017131448A patent/RU2728796C2/ru active
- 2016-03-02 BR BR112017018964A patent/BR112017018964A2/pt not_active Application Discontinuation
- 2016-03-02 EP EP16762150.7A patent/EP3265091A4/en active Pending
- 2016-03-02 US US15/555,956 patent/US10076518B2/en active Active
- 2016-03-02 WO PCT/US2016/020396 patent/WO2016144636A1/en not_active Ceased
- 2016-03-02 AU AU2016229295A patent/AU2016229295B2/en active Active
- 2016-03-02 MY MYPI2017703256A patent/MY194341A/en unknown
- 2016-03-02 JP JP2017546767A patent/JP6904570B2/ja active Active
-
2017
- 2017-08-31 IL IL254262A patent/IL254262A0/en unknown
- 2017-09-04 CL CL2017002242A patent/CL2017002242A1/es unknown
- 2017-09-05 ZA ZA2017/06035A patent/ZA201706035B/en unknown
-
2018
- 2018-09-05 US US16/122,482 patent/US10357491B2/en active Active
-
2021
- 2021-02-22 JP JP2021026411A patent/JP7264331B2/ja active Active
- 2021-10-19 AU AU2021254549A patent/AU2021254549B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507245A5 (https=) | ||
| Klinger et al. | Clinical efficacy of deep brain stimulation for the treatment of medically refractory epilepsy | |
| Villamar et al. | Noninvasive brain stimulation to modulate neuroplasticity in traumatic brain injury | |
| RU2017131448A (ru) | Способ лечения опухоли головного мозга | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| Kim et al. | Hallmarks of treatment aspects: Parkinson's disease throughout centuries including l-Dopa | |
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| JP2021091695A5 (https=) | ||
| CO2019012856A2 (es) | Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf | |
| MX2019002917A (es) | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. | |
| MX2017000806A (es) | Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos. | |
| EA201992010A1 (ru) | Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты | |
| PH12015502046A1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| CY1119371T1 (el) | Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων | |
| MX2016015436A (es) | Compuestos para tratar el cancer cerebral. | |
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| MX2016008072A (es) | Compuestos al receptor-3 del factor de crecimiento del fibroplasto (fgfr3) y metodos de tratamiento. | |
| MX2024006768A (es) | Compuestos y usos de los mismos. | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| EP4389894A3 (en) | Riboswitch modulated gene therapy for retinal diseases | |
| CO2018012061A2 (es) | Derivados de 2-anilinopirimidina como agentes terapéuticos para el tratamiento de cánceres cerebrales | |
| PH12016502432A1 (en) | 1h-1,8-naphthyridin-2-ones as anti proliferative compounds | |
| MX2019014842A (es) | Uso de una combinación de ivosidenib y radiación para tratar gliomas. | |
| CO2019007115A2 (es) | Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral | |
| Iorio-Morin et al. | Pain Disorders |